Rapport is a clinical-stage biopharmaceutical company focused on the discovery and development of transformational small molecule medicines for patients suffering from central nervous system (CNS) disorders. Our unique approach is based on the pioneering discoveries made by our founders that receptor associated proteins (RAPs) play crucial roles in regulating receptor expression and function. Targeting RAPs enables the development of CNS drugs that are more specific for receptor variants and certain neuroanatomical regions and thus have the potential to overcome the challenges of conventional neurology drugs. This deep understanding of RAP biology forms the basis of our RAP technology platform, which has the potential to provide a differentiated approach to generating precision small molecule product candidates.

Supported by a leadership team, board of directors and scientific advisory board with decades of experience building novel therapeutic platforms and commercializing products, Rapport has built a robust pipeline of candidates with the potential to support multiple indications. Our accomplished scientific team is advancing an exciting pipeline of clinical programs, led by RAP-219 in focal epilepsy, peripheral neuropathic pain, and bipolar disorder. Additional preclinical and late-stage discovery stage programs are also underway, targeting CNS disorders including chronic pain and hearing disorders.

By leveraging our expertise in RAP biology, we believe we have the potential to provide a transformative benefit for large patient populations in CNS disorders with significant unmet need.